BRPI1012980A2 - dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas - Google Patents

dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas

Info

Publication number
BRPI1012980A2
BRPI1012980A2 BRPI1012980A BRPI1012980A BRPI1012980A2 BR PI1012980 A2 BRPI1012980 A2 BR PI1012980A2 BR PI1012980 A BRPI1012980 A BR PI1012980A BR PI1012980 A BRPI1012980 A BR PI1012980A BR PI1012980 A2 BRPI1012980 A2 BR PI1012980A2
Authority
BR
Brazil
Prior art keywords
drugs
methods
cell response
neoplastic cell
cellular responsiveness
Prior art date
Application number
BRPI1012980A
Other languages
English (en)
Inventor
Alberto Orfao
Andrew Bosanquet
Consuelo Tudela
Coyt Jackson
Daniel Primo
Juan Ballesteros
Julian Gorrochategui
Lilia Suarez
Luis Ignacio Caveda
Maria Matoses
Pilar Hernandez
Sandra Sapia
Santiago Lago
Teresa Bennett
Original Assignee
Vivia Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42342776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012980(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vivia Biotech Sl filed Critical Vivia Biotech Sl
Publication of BRPI1012980A2 publication Critical patent/BRPI1012980A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1012980A 2009-05-19 2010-05-19 dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas BRPI1012980A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17968509P 2009-05-19 2009-05-19
PCT/US2010/035474 WO2010135468A1 (en) 2009-05-19 2010-05-19 Methods for providing personalized medicine tests ex vivo for hematological neoplasms

Publications (1)

Publication Number Publication Date
BRPI1012980A2 true BRPI1012980A2 (pt) 2016-03-29

Family

ID=42342776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012980A BRPI1012980A2 (pt) 2009-05-19 2010-05-19 dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas

Country Status (17)

Country Link
US (2) US20100298255A1 (pt)
EP (1) EP2433124B1 (pt)
JP (1) JP5851984B2 (pt)
CN (1) CN102460165B (pt)
AR (1) AR076590A1 (pt)
AU (1) AU2010249593B2 (pt)
BR (1) BRPI1012980A2 (pt)
CA (1) CA2762783C (pt)
CL (1) CL2011002905A1 (pt)
DK (1) DK2433124T3 (pt)
ES (1) ES2628219T3 (pt)
IL (1) IL216419A (pt)
MX (1) MX2011012267A (pt)
RU (1) RU2636614C2 (pt)
SG (2) SG10201402346UA (pt)
TW (1) TWI546537B (pt)
WO (1) WO2010135468A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130226469A1 (en) * 2008-04-01 2013-08-29 Purdue Research Foundation Gate-free flow cytometry data analysis
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
WO2012072823A1 (en) 2010-12-03 2012-06-07 Mindseeds Laboratories Srl Rapid screening of monoclonal antibodies
TWI503545B (zh) * 2010-12-24 2015-10-11 Methods of Screening Probiotics for Individual Differences
EP2707723B1 (en) * 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
HUE043001T2 (hu) 2011-11-09 2019-07-29 Bristol Myers Squibb Co Hematológiai malignómák kezelése anti-CXCR4 antitesttel
KR101327533B1 (ko) * 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 환자 맞춤형 항암제 선별용 시스템
ES2684591T3 (es) 2013-07-29 2018-10-03 The Regents Of The University Of California Plataforma de tecnología de control de sistema de retroalimentación en tiempo real con estimulaciones que cambian dinámicamente
EP2959904A1 (en) 2014-06-27 2015-12-30 Institut De Recerca Contra La Leucemia Josep Carreras Methods for treating, diagnosing and prognosing a haematological malignancy
CN104606207A (zh) * 2015-02-09 2015-05-13 南京格耀生物科技有限公司 磺胺甲恶唑在制备抑制肿瘤细胞转移和扩散的药物中的应用
CN104958312A (zh) * 2015-05-14 2015-10-07 四川大学华西医院 一种治疗急性淋巴细胞白血病的联合用药物
KR20180070603A (ko) * 2015-11-04 2018-06-26 비비아 바이오테크 에스.엘. 약물 또는 약물 조합에 대한 원발성 세포 집단의 세포 응답성을 시험하기 위한 생체외 방법
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
ES3056995T3 (en) 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
CN106093394B (zh) * 2016-06-07 2017-12-26 中国人民解放军第二军医大学 Flt3蛋白在制备肝癌对索拉菲尼疗效评估试剂盒中的应用
WO2017216739A1 (en) 2016-06-14 2017-12-21 Cellply S.R.L. Screening kit and method
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
CN111295588A (zh) 2017-10-31 2020-06-16 分子医学研究中心责任有限公司 确定测试化合物选择性的方法
US11116692B2 (en) 2018-06-07 2021-09-14 Gecko Alliance Group Inc. Method, system, computer program product and device for facilitating centralized control and monitoring over a network of a set of remote bathing unit systems
WO2020043716A1 (en) * 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis
EP3853859A1 (en) * 2018-10-11 2021-07-28 Vivia Biotech, S.L. A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug combinations in treatment of said subject
CA3119297A1 (en) * 2018-11-14 2020-05-22 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
EP3887395A4 (en) * 2018-11-30 2022-07-27 Intima Bioscience, Inc. METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES
US12560590B2 (en) 2019-01-23 2026-02-24 Massachusetts Institute Of Technology Rapid analysis of live cells
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113975659B (zh) 2020-07-27 2024-07-30 佳能医疗系统株式会社 放射线治疗辅助系统及方法
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
WO2022189453A1 (en) * 2021-03-10 2022-09-15 University Of Dundee Cell analysis
CN115531391B (zh) * 2022-11-03 2023-07-18 浙江大学 一种治疗白血病的药物及应用
CN116808176B (zh) 2023-08-30 2023-12-05 上海彗天锦泽生物医学科技有限公司 一种基于免疫检查点阻断的抗肿瘤药物组合物及其应用
WO2025172529A1 (en) 2024-02-16 2025-08-21 Medizinische Universität Wien New methods for assessing cell-specific drug response
WO2026093568A1 (en) * 2024-11-04 2026-05-07 Vivia Biotech, S.L. A method to determine simultaneously anti-cancer activity and hematotoxicity of an antibody-drug conjugate

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2947289A (en) * 1988-01-04 1989-08-01 Oncotech Incorporated Methods and apparatus assessing tumor resistance
US5366885A (en) * 1992-06-09 1994-11-22 Barranco Iii Sam C Method and kit for testing tumors for drug sensitivity
US5474909A (en) * 1992-08-07 1995-12-12 Anticancer, Inc. Noncolorimetric histoculture method for predicting drug response of tumors
AU2265695A (en) * 1995-01-17 1996-08-07 Pfizer Inc. The use of sertraline to treat cancer patients
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US5736129A (en) * 1995-11-17 1998-04-07 Medenica; Rajko D. Flow cytometric pharmacosensitivity assay and method of cancer treatment
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US20030049618A1 (en) * 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6207717B1 (en) * 1999-01-12 2001-03-27 Dow Corning Corporation Entrapment of vitamins with an elastomeric silicone polyether
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6911306B1 (en) * 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
WO2001032677A1 (en) * 1999-11-04 2001-05-10 Human Genome Sciences, Inc. Uteroglobin-like polynucleotides, polypeptides, and antibodies
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
AU2002239771A1 (en) * 2000-11-13 2002-06-18 Vanderbilt University Methods of predicting chemotherapy response
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
KR20030070150A (ko) * 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Pde4 이소자임 억제제로서 유용한 에테르 유도체
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002065121A1 (de) * 2001-02-14 2002-08-22 Evotec Oai Ag Dispensionsvorrichtung
AU2002305099A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
JP2005508171A (ja) * 2001-11-02 2005-03-31 タノックス インコーポレーテッド B細胞悪性病変の診断及び予防に用いるためのb細胞リンパ腫特異抗原
WO2003062792A2 (en) * 2002-01-22 2003-07-31 Trustees Of The University Of Pennsylvania Methods for determining drug responsiveness
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
GB0203276D0 (en) * 2002-02-12 2002-03-27 Novartis Ag Organic compounds
DE10214388A1 (de) * 2002-03-30 2003-10-16 Cognis Deutschland Gmbh Verfahren zur Herstellung fester Mittel
US7326733B2 (en) * 2002-05-31 2008-02-05 The Forsyth Institute Methods for increasing bone density
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
CN1389462A (zh) * 2002-07-12 2003-01-08 复旦大学 大叶蒟素及其同系物,和在制备药物组合物中的应用
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
US20040101477A1 (en) * 2002-11-27 2004-05-27 Xanthus Life Sciences, Inc. Individualization of therapy with anesthetics
EP1631669A2 (en) * 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US20050136043A1 (en) * 2003-08-07 2005-06-23 Ludwig Institute For Cancer Research TGFbeta signaling inhibitors
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
US20050143378A1 (en) * 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050182011A1 (en) * 2003-11-13 2005-08-18 Eric Olson Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
US7211275B2 (en) * 2004-01-16 2007-05-01 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
JP2007523121A (ja) * 2004-02-19 2007-08-16 ノバルティス アクチエンゲゼルシャフト 血管性鬱病の処置のためのコリンエステラーゼ阻害剤の使用
KR101462825B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
ATE455777T1 (de) * 2004-07-23 2010-02-15 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
US7566548B2 (en) * 2004-08-13 2009-07-28 University Of Massachusetts Methods for identifying therapeutic agents and for treating disease
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
EP1627610A1 (en) * 2004-08-21 2006-02-22 TLT Medical Ltd Drug delivery throug application in nails
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US7326171B2 (en) * 2004-09-10 2008-02-05 Otologics, Llc Adjustable bone bracket
US20060058966A1 (en) * 2004-09-15 2006-03-16 Bruckner Howard W Methods and systems for guiding selection of chemotherapeutic agents
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
WO2006045053A2 (en) * 2004-10-20 2006-04-27 Hitachi Chemical Company, Ltd. Method for tailoring administration of drugs by quantitation of mrna
CA2586179C (en) * 2004-11-02 2011-02-08 Pfizer Inc. Sulfonyl benzimidazole derivatives
CA2596543A1 (en) * 2004-11-12 2006-05-18 Northwestern University Methods of treating hematological malignancies with nucleoside analog drugs
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
WO2006084031A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
CN101201349B (zh) * 2005-03-17 2011-10-12 希森美康株式会社 试料分析装置和试料分析方法以及血液分析装置
US7601355B2 (en) * 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US7655421B2 (en) * 2005-06-17 2010-02-02 Ciencia, Inc. Cytometer on a chip
CA2613818C (en) * 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US20090118288A1 (en) * 2005-07-21 2009-05-07 Astrazeneca Ab N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor
WO2007015926A2 (en) * 2005-07-25 2007-02-08 Oregon Health And Science University Multiparameter flow cytometric cytometric cytotoxicity systems, methods, compositions and kits for evaluating the susceptibility of cancer
AR058071A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas.
CN101351563A (zh) * 2005-10-05 2009-01-21 阿斯利康(英国)有限公司 用于预测或监测病人对于ErbB受体药物的响应的方法
US20080318252A1 (en) * 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
WO2007063391A2 (en) * 2005-12-02 2007-06-07 Pfizer Limited Spirocyclic quinazoline derivatives as pde7 inhibitors
CA2631494A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
EP1998788A4 (en) * 2006-03-01 2011-08-03 Ruey J Yu COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR
US7700618B2 (en) * 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US20090029958A1 (en) * 2006-03-08 2009-01-29 Lilian Alcaraz Phenethanolamine derivatives as beta2 adrenoreceptor agonists
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
WO2007139895A2 (en) * 2006-05-24 2007-12-06 Cellumen, Inc. Method for modeling a disease
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
AU2007265239A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
HUE035389T2 (en) * 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
US8841300B2 (en) * 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US7661326B2 (en) * 2006-10-26 2010-02-16 Beckman Coulter, Inc. Apparatus for aspirating and dispensing liquids in an automated analyzer
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
CN101677957A (zh) * 2007-02-05 2010-03-24 卡比兰生物外科公司 用于递送生物活性试剂的聚合物制剂
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
JP2010520306A (ja) * 2007-03-07 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−αモジュレーターとしての置換フェノキシチアゾリジンジオン
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
HRP20191104T1 (hr) * 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US8354417B2 (en) * 2007-09-26 2013-01-15 Celgene Corporation Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
WO2009051238A1 (ja) * 2007-10-18 2009-04-23 Riken ヒト白血病幹細胞および白血病非幹細胞が増幅されたマウスおよびその製造方法
CN101896184A (zh) * 2007-10-19 2010-11-24 伯恩哈姆医学研究协会 抗凋亡蛋白抑制剂
US9115061B2 (en) * 2007-10-19 2015-08-25 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
PT2297106E (pt) * 2008-05-27 2014-09-29 Astrazeneca Ab Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
EP2304436A1 (en) * 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
KR101046883B1 (ko) * 2008-11-19 2011-07-06 재단법인 아산사회복지재단 항암제 치료약제에 대한 감수성을 일괄적으로 결정하는 방법

Also Published As

Publication number Publication date
CA2762783A1 (en) 2010-11-25
IL216419A0 (en) 2012-02-29
SG176571A1 (en) 2012-01-30
US20170205395A1 (en) 2017-07-20
CL2011002905A1 (es) 2012-07-13
RU2636614C2 (ru) 2017-11-24
JP5851984B2 (ja) 2016-02-03
ES2628219T3 (es) 2017-08-02
EP2433124B1 (en) 2017-03-01
SG10201402346UA (en) 2014-10-30
RU2011148289A (ru) 2013-06-27
MX2011012267A (es) 2012-04-11
AU2010249593A1 (en) 2012-01-12
WO2010135468A1 (en) 2010-11-25
IL216419A (en) 2016-05-31
TWI546537B (zh) 2016-08-21
CN102460165B (zh) 2016-08-17
EP2433124A1 (en) 2012-03-28
CN102460165A (zh) 2012-05-16
JP2012527627A (ja) 2012-11-08
US20100298255A1 (en) 2010-11-25
TW201043955A (en) 2010-12-16
AR076590A1 (es) 2011-06-22
DK2433124T3 (en) 2017-06-19
AU2010249593B2 (en) 2016-03-17
CA2762783C (en) 2018-06-26

Similar Documents

Publication Publication Date Title
BRPI0921726A2 (pt) método e dispositivo para ativar células tronco
IL254144A0 (en) Methods for reprogramming cells and uses thereof
BRPI0912680A2 (pt) sistema e métodos para medição e análise do consumo de energia de eventos dentro de um dispositivo portátil
BRPI0911758A2 (pt) anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos
BRPI1015026A2 (pt) método e aparelho para facilitar os procedimentos de medição em operação de multiportadora.
BRPI0818011A2 (pt) Método e dispositivo para associar objetos
BR112012011910A2 (pt) dispositivo e método
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
DK2688629T3 (da) Urinopsamlingsenhed og fremgangsmåde til fremstilling deraf
BRPI1106096A2 (pt) dispositivo de monitoramento de material analítico e métodos.
BRPI0909657A2 (pt) dispositivo espaçador intersomático expansível
BR112012005568A2 (pt) aparelho e métodos para medir processos biológicos
BRPI0918294A2 (pt) dispositivo e método para produzir explosões
BRPI0821617A2 (pt) Dispositivos e métodos para reatores de fluxo contínuo alveolados
BRPI0924215A2 (pt) método e sistema para execução de medição
BRPI0812236A2 (pt) Método e dispositivo para a detecção de água em uma estruturas celular
BRPI0820007A2 (pt) Dispositivo e método para conectar tiras
BRPI1013533A2 (pt) aparelho e método para suportar múltiplos serviços
BRPI0907150A8 (pt) dispositivo e método para microelastografia
EP2510352A4 (en) APPARATUS FOR COLLECTING AND SAMPLE ANALYSIS
BR112012000477A2 (pt) módulo de tensão de furo de sondagem e métodos para uso
EP2432073A4 (en) ANTENNA ASSESSMENT APPARATUS AND ANTENNA ASSESSMENT METHOD
FI20075686A0 (fi) Konfigurointimenetelmä ja -laite
BRPI1007890A2 (pt) dispositivo e método para perfurar material
BR112013012248A2 (pt) dispositivo e método para imunotestes

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements